psychiatryRounds

Connecting Psychiatry - Expert community for all mental health professionals

(PSYCHIATRIC TIMES) - MedPage Today Action Points

o Explain to patients who ask that there is currently no strong evidence to support the use of NSAIDs for primary prevention of Alzheimer's disease or related forms of dementia. In fact, evidence from the ADAPT study hints at a possible negative effect of naproxen (Aleve) and celecoxib (Celebrex) on dementia risk.

BALTIMORE, April 25 -- Neither naproxen (Aleve) nor celecoxib (Celebrex) reduced the risk of developing Alzheimer's disease, at least in the short term, investigators from the suspended ADAPT trial reported.

According to results of the randomized study funded by the National Institute on Aging, there was even a suggestion that both naproxen and celecoxib were associated with a slightly increased risk of dementia, reported Constantine Lyketsos, M.D., M.H.S., of Johns Hopkins, and colleagues in the ADAPT trial.

For full article, please visit:
http://www.psychiatrictimes.com/alzheimer-dementia/article/10168/58506

Views: 4

Comment

You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds


psychiatryRounds Social Media

Sponsors

CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2019   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service